Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 8/2018

01-08-2018 | Ischemic Heart Disease (D Mukherjee, Section Editor)

Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients

Authors: Lima Lawrence, Venu Menon, Sangeeta Kashyap

Published in: Current Cardiology Reports | Issue 8/2018

Login to get access

Abstract

Purpose of Review

We review the cardiovascular and renal outcomes and safety of newer anti-diabetic medications in high-risk patients. We examine the outcomes of the IRIS, EMPA-REG OUTCOME, CANVAS, LEADER, SAVOR-TIMI 53, and EXAMINE trials demonstrating the cardiovascular and renal benefits of thiazolidinediones, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors.

Recent Findings

Diabetes mellitus is a leading risk factor for cardiovascular disease with rising prevalence and disease burden. The microvascular and macrovascular complications of diabetes are well-recognized and include increased risk of cardiovascular disease, myocardial infarction, and stroke. Newer diabetes medications have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality benefits in high risk patients with diabetes. In addition to their glucose-lowering effects, the thiazolidinedione pioglitazone, SGLT2 inhibitors, GLP-1 agonist, and DPP-4 inhibitors have demonstrated significant cerebrovascular, cardiovascular, renal, and mortality effects.

Summary

The outcomes and safety data of newer diabetes medications from recent trials demonstrate cardiovascular and mortality effects with significant implications for clinical practice.
Literature
1.
Di Angelantoni E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;324:52–60.
2.
Golden S. Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications. Am J Card. 2011;108:59B–67B.CrossRefPubMed
3.
National Diabetes Statistics Report. Centers for disease control. 2017
4.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM. 2008;358:2545–59.CrossRef
5.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
6.
Holman R, Paul S, Bethel M, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM. 2008;359:1577–89.CrossRefPubMed
7.
•• Kernan W, Viscoli C, Furie K, et al. Pioglitazone after ischemic stroke or transient ischemic attack. NEJM. 2016;374:1321–31. This is a publication of the IRIS trial methods, findings and conclusions. CrossRefPubMed
8.
•• Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015;373:2117–28. This is a publication of the EMPA-REG trial methods, findings and conclusions. CrossRefPubMed
9.
•• Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. NEJM. 2017;377:644–57. This is a publication of the EMPA-REG trial methods, findings and conclusions. CrossRefPubMed
10.
•• Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. NEJM. 2016;374:311–22. This is a publication of the cardiovascular outcomes of the LEADER Trials. CrossRef
11.
Scirica B, Bhatt D, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEJM. 2013;369:1317–26.CrossRefPubMed
12.
White W, Cannon C, Heller S, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEJM. 2013;369:1327–35.CrossRefPubMed
13.
Chiarelli F, Di Marzio D. Peroxisome proliferator-activated receptor-γ agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008;4:297–304.CrossRefPubMedPubMedCentral
14.
Mearns E, Saulsberry W, White C, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med. 2015;32:1530–40.CrossRefPubMed
15.
16.
17.
Saad M, Mahmoud A, Elgendy I, et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: a meta-analysis of placebo-controlled randomized trials. Int J Cardiol. 2017;228:352–8.CrossRefPubMed
18.
Syed S, Gosavi S, Shami W, Bustamante M, Farah Z, Teleb M, et al. A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin. Cardiovasc Hematol Agents Med Chem. 2015;13(2):105–12.CrossRefPubMed
19.
Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.CrossRefPubMedPubMedCentral
20.
Kalra S, Baruah M, Sahay R, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J Endocrinol Metab. 2016;20:254–67.CrossRefPubMedPubMedCentral
21.
Knudsen L, Madsen L, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–86.CrossRef
22.
•• Mann J, Orsted D, Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. NEJM. 2017;377:839–48. This is a publication of the renal outcomes from the LEADER Trials. CrossRefPubMed
23.
Ussher J, Drucker D. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788–803.CrossRefPubMed
24.
Fujita H, Morii T, Fujishima H, Sato T, Shimizu T, Hosoba M, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85:579–89.CrossRefPubMed
25.
Thornberry N, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23:479–86.CrossRefPubMed
26.
27.
Said S, Nwosu A, Mukherjee D, Hernandez G. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. Cardiovasc Hematol Disord Drug Targets. 2014;14(1):64–70.CrossRefPubMed
28.
Graham D, Ouellet-Hellstrom R, MaCurdy T, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.CrossRefPubMed
29.
• Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. NEJM. 2015;373:2247–57. This study details the noninferiority of GLP-1 agonist, lixisenatide to placebo in cardiovascular outcomes. CrossRefPubMed
30.
Schernthaner G, Cahn A, Raz I. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes Care. 2016;39:S210–8.CrossRefPubMed
31.
• Green J, Bethel M, Armstrong P, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. NEJM. 2015;373:232–42. This study details the noninferiority of DPP-4 inhibitor, sitagliptin to placebo in cardiovascular outcomes. CrossRefPubMed
32.
Filion K, Azoulay L, Platt R, Dahl M, Dormuth CR, Clemens KK, et al. A multicenter observational study of incretin-based drugs and heart failure. NEJM. 2016;374:1145–54.CrossRefPubMed
33.
Fu A, Johnston S, Ghannam A, et al. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study. Diabetes Care. 2016;39:726–34.CrossRefPubMed
34.
Li L, Li S, Deng K, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ. 2016;352:i610.CrossRefPubMedPubMedCentral
35.
Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol. 2016;211:88–95.CrossRefPubMed
Metadata
Title
Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Authors
Lima Lawrence
Venu Menon
Sangeeta Kashyap
Publication date
01-08-2018
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 8/2018
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-018-1005-8

Other articles of this Issue 8/2018

Current Cardiology Reports 8/2018 Go to the issue

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?

Ischemic Heart Disease (D Mukherjee, Section Editor)

Gender Disparities in Presentation, Management, and Outcomes of Acute Myocardial Infarction

Lipid Abnormalities and Cardiovascular Prevention (G De Backer, Section Editor)

Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias

Regenerative Medicine (SM Wu, Section Editor)

Cardiomyocyte Proliferation for Therapeutic Regeneration

Pericardial Disease (AL Klein, Section Editor)

Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases

Congenital Heart Disease (RA Krasuski, Section Editor)

Long-term Management of the Arterial Switch Patient